Kleisbauer J P, Vesco D, Orehek J, Blaive B, Clary C, Poirier R, Saretto S, Carles P, Dongay G, Guerin J C
Hôpital Salvator, Marseille, France.
Eur J Cancer Clin Oncol. 1988 Feb;24(2):131-5. doi: 10.1016/0277-5379(88)90243-x.
To study the efficacy of etoposide in brain metastases of lung carcinoma, etoposide was given during 3 consecutive days. The total dose of 1500 mg/m2 was divided into six 1 h perfusions delivered over 3 days to 19 patients having squamous (7), large cell (3), small cell (5) or adenocarcinoma (4). Response to chemotherapy was assessed by means of computerized tomography (CT) before and 15-30 days after the last course of chemotherapy (course interval = 28 days, maximum of four courses). Severe myelotoxicity was observed in nine patients with seven patient deaths resulting from infection. Efficacy could be evaluated in 13 patients. Failure was observed in seven cases. An objective response was observed in six patients (4/14 NSCLC and 2/5 SCLC), two patients having a complete regression. Average survival time was 10 weeks.
为研究依托泊苷治疗肺癌脑转移的疗效，连续3天给予依托泊苷。1500mg/m²的总剂量分为6次，在3天内进行1小时灌注，给药对象为19例患有鳞状细胞癌（7例）、大细胞癌（3例）、小细胞癌（5例）或腺癌（4例）的患者。在最后一个化疗疗程前及化疗后15 - 30天通过计算机断层扫描（CT）评估化疗反应（疗程间隔 = 28天，最多四个疗程）。9例患者出现严重骨髓毒性，7例患者因感染死亡。13例患者的疗效可进行评估。7例观察到治疗失败。6例患者出现客观反应（非小细胞肺癌14例中的4例和小细胞肺癌5例中的2例），2例患者完全缓解。平均生存时间为10周。
